US › Healthcare

Arbutus Biopharma Corp (ABUS)

US · Healthcare · Biotechnology

$4.42+1.38%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$179.1M
Revenue YoY
+10054.5%
Net profit
$169.7M
Profit YoY
+791.9%
EPS
$1.19
EPS estimate
$-0.05
Net margin
94.7%

EPS came in at 1.19 against a street estimate of -0.05 — a beat of 2480.0%.

Key statistics

Market cap
$857.3M
P/E
5.2
Forward P/E
10.2
P/B
3.30
Book value
$1.32
EPS (TTM)
$0.83
52-week high
$5.38
52-week low
$3.30
50-day MA
$4.52
200-day MA
$4.45
Beta
0.62

Analyst view

Analysts rate Arbutus Biopharma Corp a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $5.50.

Shareholding

Insiders
20.46%
Institutions
72.09%

Largest institutional holders

FundStake
Morgan Stanley - Brokerage Accounts13.11%
Two Seas Capital LP9.39%
Whitefort Capital Management, LP.7.56%
BlackRock Inc6.56%
Vanguard Capital Management, LLC3.39%
Rubric Capital Management LP3.35%
State Street Corp3.21%
Barclays PLC2.18%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Arbutus Biopharma Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.